Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: Identification of a novel p63/Her2/neu expressing subgroup

Oncotarget

Volumn 4, Issue 2, 2013, Pages 231-241

  Shekhar, Malathy P V ^a,b   Kato, Ikuko ^a,b   Nangia Makker, Pratima ^a,b   Tait, Larry ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Cytokeratin; EGFR; Her2 neu; P63

Indexed keywords

CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P63;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOGENESIS; CANCER INVASION; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL ARTICLE; COMEDO DUCTAL CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84875781320     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.818     Document Type: Article

References (41)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U.S.A. 2001; 98: 10869-10874.
3. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 192: 264-271.
4. Cassol L, Silveira Graudenz M, Zelmanowicz A, Cancela A, Werutsky G, Rovere RK, Garicochea B. Basal-like immunophenotype markers and prognosis in early breast cancer. Tumori. 2010; 96: 966-970.
5. Burness ML, Grushko TA, Olopade OI. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J. 2010; 16: 23-32.
6. Ribeiro-Silva A, Ramalho LN, Garcia SB, Brandão DF, Chahud F, Zucoloto S. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathol. 2005; 47: 458-466.
7. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005; 447: 688-694.
8. Laakso M, Loman N, Borg A, Isola J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005; 18: 1321-1328.
9. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374.
10. Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005; 7: 143-148.
11. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis O. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004; 203: 661-671.
12. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews NC, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-316.
13. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci. 2000; 113: 1661-1670.
14. Barbaresch M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Doglioni C. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol. 2001; 25: 1054-1060.
15. Werling RW, Hwang H, Yaziji H, Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol. 2003; 27: 82-90.
16. Ribeiro-Silva A, Zambelli Ramalho LN, Britto Garcia S, Zucoloto S. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med. 2003; 127: 336-340.
17. Fisher ER, Land SR, Saad RS, Fisher B, Wickerham DL, Wang M, Constantino JP, Wolmark N. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am J Clin Pathol. 2007; 128: 86-91.
18. Silverstein, MJ. Ductal Carcinoma In Situ of the Breast: Controversial Issues. The Oncologist 1998; 3: 94-103.
19. Moinfar F, Mannion C, Man YG, Tavassoli FA. Mammary "comedo"-DCIS: apoptosis, oncosis, and necrosis: an electron microscopic examination of 8 cases. Ultrastruct Pathol. 2000; 24: 135-144.
20. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS. com xenograft model of human comedo ductal carcinoma in situ. J Nat Cancer Inst. 2000; 92: 1185-1186.
21. Tait LR, Pauley RJ, Santner SJ, Heppner GH, Heng HH, Rak JW, Miller FR. Dynamic stromal epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer 2007; 120: 2127-2134.
22. Shekhar MP, Tait L, Pauley RJ, Wu GS, Santner SJ, Nangia-Makker P, Shekhar V, Nassar H, Visscher DW, Heppner GH, Miller FR. Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. Cancer Biol Ther. 2008; 7: 1774-1782.
23. Gerard B, Tait L, Nangia-Makker P, Shekhar MP. Rad6B acts downstream of Wnt signaling to stabilize β-catenin: Implications for a novel Wnt/β-catenin target. J Mol Signal. 2011; 6:6.
24. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002; 82: 1525-1533.
25. Diehl KM, Grewal N, Ethier SP, Woods-Ignatoski KM. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal. J Surg Res. 2007; 142: 162-169.
26. Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 2007; 26: 7163-7169.
27. Pervez S, Khan H. Infiltrating ductal carcinoma breast with central necrosis closely mimicking ductal carcinoma in situ (comedo type): a case series. J Med Case Reports 2007; 1: 83.
28. Nagle RB, Böcker W, Davis JR, Heid HW, Kaufmann M, Lucas DO, Jarasch ED. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem. 1986; 34: 869-881.
29. Otterbach F, Bankfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathol 2000; 37: 232-240.
30. Jarasch ED, Nagle RB, Kaufman M, Maurer C, Böcker WJ. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 1988; 19: 276-289.
31. Böcker W, Moll R, Poremba C, Holland R, van Diest PJ, Dervan P, Burger J, Wai D, Diallo RI, Brandt B, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 2002; 82: 737-745.
32. Anbazhagan R, Osin PP, Bartkova J, Nathan B, Lane EB, Gusterson BA. The development of epithelial phenotypes in the human fetal and infant breast. J Pathol. 1998; 184: 197-206.
33. Aasmundstad TA, Haugen OA. DNA ploidy in intraductal breast carcinomas. Eur J Cancer 1992; 26: 956-959.
34. Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat.1986; 7: 171-180.
35. Barnes DM, Meyer JS, Gonzalez JG, Gullick WJ, Millis RR. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Breast Cancer Res Treat. 1991; 18: 11-17.
36. Bartkova J, Barnes DM, Millis RR, Gullick WJ. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol. 1990; 21: 1164-1167.
37. Lagios NM, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63: 618-624.
38. Schwartz GF. The role of excision and surveillance alone in subclinical DCIS of the breast. Oncology 1994; 8: 21-26.
39. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Modern Pathol. 2006; 19: 1506-1511.
40. Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP. Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells. Neoplasia 2005; 7: 88-798.
41. Shekhar MP, Gerard B, Pauley RJ, Williams BO, Tait L. Rad6B is a positive regulator of beta-catenin stabilization. Cancer Res. 2008; 68: 1741-1750.